0000950170-24-012476.txt : 20240207 0000950170-24-012476.hdr.sgml : 20240207 20240207215610 ACCESSION NUMBER: 0000950170-24-012476 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240207 FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vida Ventures, LLC CENTRAL INDEX KEY: 0001724489 ORGANIZATION NAME: STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41947 FILM NUMBER: 24606654 BUSINESS ADDRESS: STREET 1: 40 BROAD STREET, SUITE 201 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: (857) 254-9492 MAIL ADDRESS: STREET 1: 40 BROAD STREET, SUITE 201 CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kyverna Therapeutics, Inc. CENTRAL INDEX KEY: 0001994702 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831365441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5980 HORTON STREET STREET 2: SUITE 550 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5106268331 MAIL ADDRESS: STREET 1: 5980 HORTON STREET STREET 2: SUITE 550 CITY: EMERYVILLE STATE: CA ZIP: 94608 3 1 ownership.xml 3 X0206 3 2024-02-07 0 0001994702 Kyverna Therapeutics, Inc. KYTX 0001724489 Vida Ventures, LLC 40 BROAD STREET, SUITE 201 BOSTON MA 02109 false false true false Series A-1 Redeemable Convertible Preferred Stock Common Stock 967188 D Series A-2 Redeemable Convertible Preferred Stock Common Stock 1940388 D Series B Redeemable Convertible Preferred Stock Common Stock 1616348 D The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock has no expiration date and is convertible into the Issuer's Common Stock on a 1-for-4.5511 basis at any time. The number of underlying shares of Common Stock reported in Column 3 reflects an automatic conversion of each outstanding share of Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock into shares of Common Stock at a ratio of 1-for-4.5511 to be effective immediately prior to the closing of the Issuer's initial public offering. Vida Ventures Advisors, LLC is the investment advisor to the Reporting Person. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by the Reporting Person, but each disclaims beneficial ownership of the shares held by the Reporting Person except to the extent of such person's pecuniary interest therein, if any. Vida Ventures, LLC, By: /s/ Fred Cohen, Director 2024-02-07